公开(公告)号：US06399076B2

公开(公告)日：2002-06-04

申请号：US08945750

申请日：1998-06-09

申请人： John R. Vose ,  Raafat E. F. Fahim ,  Gail E. D. Jackson ,  Larry U. L. Tan ,  Andrew Herbert ,  Leslie Boux ,  Luis Barreto ,  John Thipphawong ,  Michel H. Klein

发明人： John R. Vose ,  Raafat E. F. Fahim ,  Gail E. D. Jackson ,  Larry U. L. Tan ,  Andrew Herbert ,  Leslie Boux ,  Luis Barreto ,  John Thipphawong ,  Michel H. Klein

IPC分类号： A61K3910

CPC分类号： C07K14/235 ,  A61K39/00 ,  A61K39/099 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  Y02A50/466

摘要： Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be prepared from a Bordetella strain, particularly a B. pertussis strain, by a multiple step procedure involving extraction of the fimbrial agglutinogens from cell paste and concentrating and purifying the extracted material.

摘要翻译： 无细胞百日咳疫苗包括纯化的毒素或类毒素，丝状血凝素，促凝血素和菌毛凝集素，其配制为对至少70％的危险人群的成员提供保护。 菌毛凝集素可以通过涉及从细胞糊中提取菌毛凝集素的多步骤方法由博德特氏菌属菌种，特别是百日咳杆菌菌株制备，并浓缩和纯化提取的物质。

公开(公告)号：US5877298A

公开(公告)日：1999-03-02

申请号：US433646

申请日：1995-05-04

申请人： Raafat E. F. Fahim ,  John R. Vose ,  John Thipphawong ,  Luis Barreto ,  Gail E. D. Jackson ,  Larry U. L. Tan ,  Andrew Herbert ,  Michel H. Klein

发明人： Raafat E. F. Fahim ,  John R. Vose ,  John Thipphawong ,  Luis Barreto ,  Gail E. D. Jackson ,  Larry U. L. Tan ,  Andrew Herbert ,  Michel H. Klein

IPC分类号： C12N9/10 ,  A61K31/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/05 ,  A61K39/07 ,  A61K39/08 ,  A61K39/10 ,  A61K39/102 ,  A61K39/116 ,  A61K39/13 ,  A61K39/165 ,  A61K39/20 ,  A61K39/29 ,  A61K39/39 ,  A61P31/00 ,  A61P31/04 ,  A61P43/00 ,  C07K14/235 ,  C12P1/00 ,  C12P21/00 ,  A23J1/00 ,  C07K1/00

CPC分类号： C07K14/235 ,  A61K39/00 ,  A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/70

摘要： A fimbrial agglutinogen preparation is prepared from a bordetella strain, particularly a B. pertussis strain, by a multiple step procedure involving extraction of the fimbrial agglutinogens from cell paste and concentrating and purifying the extracted material. The fimbrial agglutinogen preparation may be used to prepare acellular pertussis vaccines with other pertussis antigens, including pertussis toxin or toxoid thereof, the 69 kDa protein and filamentous hemagglutinin and other Bordetella antigens.

摘要翻译： 通过多步骤程序从波尔灭菌属菌种，特别是百日咳杆菌菌株制备菌毛凝集素制剂，包括从细胞糊中提取菌毛凝集素，并浓缩和纯化提取的物质。 毛细血管凝集素制剂可用于制备其他百日咳抗原，包括百日咳毒素或其类毒素，69 kDa蛋白质和丝状血凝素和其他博德特氏菌抗原的无细胞百日咳疫苗。

公开(公告)号：US06696065B1

公开(公告)日：2004-02-24

申请号：US08672530

申请日：1996-07-02

申请人： Raafat E. F. Fahim ,  Larry U. L. Tan ,  Luis Barreto ,  John Thipphawong ,  Gail E. D. Jackson

发明人： Raafat E. F. Fahim ,  Larry U. L. Tan ,  Luis Barreto ,  John Thipphawong ,  Gail E. D. Jackson

IPC分类号： A61K3910

CPC分类号： A61K39/099 ,  A61K39/00 ,  A61K39/0018 ,  A61K39/102 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/6037 ,  A61K2039/70 ,  C07K14/235 ,  C12N2770/32634 ,  Y02A50/466

摘要： A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide on Haemophilus influenzae type b and tetanus toxoid or diphtheria toxoid, which may be reconstituted from a lyophilized state by the other component. The administration of the multiple component vaccine resulted in no diminution of the immunogenicity of any component as a result of interference by other components of the vaccine.

摘要翻译： 描述了包含无细胞百日咳疫苗组分，白喉类毒素，破伤风类毒素和灭活的脊髓灰质炎病毒的多组分疫苗组合物。 该组合物还可以含有b型流感嗜血杆菌和破伤风类毒素或白喉类毒素上的荚膜多糖的缀合物，其可由另一种组分从冻干状态重构。 多组分疫苗的施用导致由于疫苗的其它成分的干扰而导致的任何组分的免疫原性的降低。

公开(公告)号：US4966850A

公开(公告)日：1990-10-30

申请号：US340307

申请日：1989-04-19

申请人： Ernest K. C. Yu ,  Larry U. L. Tan ,  John N. Saddler

发明人： Ernest K. C. Yu ,  Larry U. L. Tan ,  John N. Saddler

IPC分类号： C12N9/24 ,  C12N9/42

CPC分类号： C12Y302/01032 ,  C12N9/2437 ,  C12N9/248 ,  C12N9/2482 ,  C12Y302/01004 ,  C12Y302/01008 ,  Y10S435/814

摘要： The present invention provides for the use in the production of cellulolytic and xylanolytic enzymes, particularly xylanase and cellulase, of the microorganism Thermoascus aurantiacus in a culture medium containing at least one of a cellulose or hemicellulose substrate whereby to produce thermostable enzymes, particularly cellulase and xylanase.

摘要翻译： 本发明提供了在含有纤维素或半纤维素底物中的至少一种的培养基中生产微生物嗜热黄曲霉的纤维素分解酶和木聚糖酶和纤维素酶的用途，由此产生热稳定酶，特别是纤维素酶和木聚糖酶 。

公开(公告)号：US4997915A

公开(公告)日：1991-03-05

申请号：US333964

申请日：1989-04-06

申请人： Larry U. L. Tan ,  Dirk Alkema ,  Gail Jackson ,  Po S. Wah

发明人： Larry U. L. Tan ,  Dirk Alkema ,  Gail Jackson ,  Po S. Wah

IPC分类号： C12P21/00 ,  A61K38/36 ,  A61K39/00 ,  A61K39/10 ,  A61P31/04 ,  C07K1/16 ,  C07K1/22 ,  C07K14/005 ,  C07K14/195 ,  C07K14/235 ,  C07K14/41 ,  C07K16/00 ,  C12R1/01

CPC分类号： C07K14/235 ,  A61K39/00

摘要： Lymphocytosis promoting factor (LPF) and filamentous hemaglutinin (FHA) are isolated from the growth medium of the Bordatella pertussis organism and purified by selecting adsorbing the LPF and FHA on a selective adsorbing medium, such as filter aids or gel filtration media, at low ionic strength and subsequently removing the adsorbed LPF and FHA at using an aqueous medium of high ionic strength, either simultaneously or sequentially. Prior to desorbtion of the LPF and FHA, the adsorbing medium may be contacted with an aqueous solution of a non-ionic detergent, which enables the LPF and FHA subsequently desorbed to be substantially free from contamination by lipopolysaccharides (LPS). The LPF and FHA may be further purified on hydroxyapatite. The LPF and FHA may be detoxified separately or together by contacting with a cross-linking agent, such as glutaraldehyde or formaldehyde, in the presence of an anti-aggregation agent. The resulting purified and detoxified LPF and FHA may be used to formulate a vaccine against pertussis.